Excelimmune, Inc., a Woburn, Mass.-based biopharmaceutical company specializing in the development of fully human recombinant polyclonal antibodies for therapeutic use, has held the final close of a $10.5m Series B financing.
The funding includes new and existing high net worth individual investors.
The company intends to use the funds to advance Staphguard, a human recombinant polyclonal antibody (HRPA) candidate against methicillin-resistant Staphylococcus aureus (MRSA), toward the clinic, and to develop its technology, which is applicable in the treatment of infectious diseases, as well as protein diseases and cancer.
Founded in 2006 and led by CEO Quinton Zondervan, Excelimmune is initially focusing on the treatment of infections caused by Staphylococcus aureus, including the drug resistant superbug, MRSA.
FinSMEs
31/05/2011